Vemurafenib-Induced Pityriasis Amiantacea: A Case Report
October 2015
in “
Cutaneous and ocular toxicology
”
TLDR Vemurafenib can cause scalp issues but can be managed without changing the dose.
This case report described a patient who developed pityriasis amiantacea (PA), a scaling reaction of the scalp that can lead to temporary or permanent hair loss, two months after starting vemurafenib therapy for BRAF-positive metastatic melanoma. This adverse effect had not been previously reported in the literature. The PA was managed with symptomatic treatment, and there was no need to alter the vemurafenib dosage.
